Tolterodine,a new antimuscarinic agent,in patients with overactive bladder

Objective To evaluate the efficacy and tolerability of tolterodine in patients with an overactive bladder. Methods A randomized,double-blind,double-simulant,parallel-controlled,multicentric study was carried out in 207 patients with bladder overactivity,patients received either tolterodine (2 mg twice daily)or oxybutynin (5 mg twice daily). Results After 8 weeks of treatment,the mean frequency of micturition decreased 3.0±3.4 times and 4.6±6.4 times in those receiving tolterodine (n=103) and oxybutynin(n=104),respectively.Among those with urge incontinence,the mean number of incontinence episodes decreased 1.5±1.8 times and 2.4±2.1 times,respectively,in those receiving tolterodine and oxybutynin.The effect of tolterodine and oxybutynin on these two micturition variables was statistically equivalent.In the tolterodine group,the total incidence of adverse event was 66.9% and the incidence of dry mouth,the most common adverse,was 55.3%.While in the oxybutynin group,the incidences were 87.5% and 76.9% respectively.The incidences of adverse events and dryness were significantly lower in those on tolterodine than in those on oxybutynin. Conclusions Tolterodine 2 mg twice daily had the equivalent efficacy on patients with overactive bladder as compared to oxybutynin 5 mg twice daily,and the adverse events of tolterodine were lower than oxybutynin.